• Something wrong with this record ?

Is KIBRA polymorphism associated with memory performance and cognitive impairment in Alzheimer's disease

V. Jurasova, R. Andel, A. Katonova, R. Nolan, Z. Lacinova, T. Kolarova, V. Matoska, M. Vyhnalek, J. Hort

. 2024 ; 102 (1) : 218-227. [pub] 20241015

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003565

BACKGROUND: Genetic variations in a common single nucleotide polymorphism in the ninth intron of the KIBRA gene have been linked to memory performance and risk of Alzheimer's disease (AD). OBJECTIVE: We examined the risk of AD related to presence of KIBRA T allele (versus CC homozygote) and to memory performance. The role of established genetic risk factors APOE ε4 and BDNF Met was also considered. METHODS: Participants were cognitively healthy individuals (n = 19), participants with amnestic mild cognitive impairment (aMCI) due to AD (n = 99) and AD dementia (n = 37) from the Czech Brain Aging Study. Binary and multinomial logistic regressions compared odds of belonging to a certain diagnostic category and multivariate linear regressions assessed associations with memory. RESULTS: KIBRA T allele was associated with increased AD dementia risk (odds ratio [OR] = 5.98, p = 0.012) compared to KIBRA CC genotype. In APOE ε4 negative individuals, KIBRA T allele was associated with a greater risk of both aMCI due to AD (OR = 6.68, p = 0.038) and AD dementia (OR = 15.75, p = 0.009). In BDNF Met positive individuals, the KIBRA T allele was associated with a greater risk of AD dementia (OR = 10.98, p = 0.050). In AD dementia, the association between KIBRA T allele and better memory performance approached significance (β = 0.42; p = 0.062). The link between possessing the KIBRA T allele and better memory reached statistical significance only among BDNF Met carriers (β = 1.21, p = 0.027). CONCLUSIONS: Findings suggest that KIBRA T allele may not fully protect against AD dementia but could potentially delay progression of post-diagnosis cognitive deficits.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003565
003      
CZ-PrNML
005      
20250206104420.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/13872877241284313 $2 doi
035    __
$a (PubMed)39497316
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jurasova, Vanesa $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
245    10
$a Is KIBRA polymorphism associated with memory performance and cognitive impairment in Alzheimer's disease / $c V. Jurasova, R. Andel, A. Katonova, R. Nolan, Z. Lacinova, T. Kolarova, V. Matoska, M. Vyhnalek, J. Hort
520    9_
$a BACKGROUND: Genetic variations in a common single nucleotide polymorphism in the ninth intron of the KIBRA gene have been linked to memory performance and risk of Alzheimer's disease (AD). OBJECTIVE: We examined the risk of AD related to presence of KIBRA T allele (versus CC homozygote) and to memory performance. The role of established genetic risk factors APOE ε4 and BDNF Met was also considered. METHODS: Participants were cognitively healthy individuals (n = 19), participants with amnestic mild cognitive impairment (aMCI) due to AD (n = 99) and AD dementia (n = 37) from the Czech Brain Aging Study. Binary and multinomial logistic regressions compared odds of belonging to a certain diagnostic category and multivariate linear regressions assessed associations with memory. RESULTS: KIBRA T allele was associated with increased AD dementia risk (odds ratio [OR] = 5.98, p = 0.012) compared to KIBRA CC genotype. In APOE ε4 negative individuals, KIBRA T allele was associated with a greater risk of both aMCI due to AD (OR = 6.68, p = 0.038) and AD dementia (OR = 15.75, p = 0.009). In BDNF Met positive individuals, the KIBRA T allele was associated with a greater risk of AD dementia (OR = 10.98, p = 0.050). In AD dementia, the association between KIBRA T allele and better memory performance approached significance (β = 0.42; p = 0.062). The link between possessing the KIBRA T allele and better memory reached statistical significance only among BDNF Met carriers (β = 1.21, p = 0.027). CONCLUSIONS: Findings suggest that KIBRA T allele may not fully protect against AD dementia but could potentially delay progression of post-diagnosis cognitive deficits.
650    _2
$a lidé $7 D006801
650    12
$a Alzheimerova nemoc $x genetika $7 D000544
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a kognitivní dysfunkce $x genetika $7 D060825
650    _2
$a senioři $7 D000368
650    12
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a intracelulární signální peptidy a proteiny $x genetika $7 D047908
650    _2
$a paměť $x fyziologie $7 D008568
650    _2
$a genetická predispozice k nemoci $x genetika $7 D020022
650    _2
$a genotyp $7 D005838
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a mozkový neurotrofický faktor $x genetika $7 D019208
650    _2
$a apolipoprotein E4 $x genetika $7 D053327
650    _2
$a alely $7 D000483
655    _2
$a časopisecké články $7 D016428
700    1_
$a Andel, Ross $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic $u Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Katonova, Alzbeta $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
700    1_
$a Nolan, Raena $u Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA
700    1_
$a Lacinova, Zuzana $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Kolarova, Tereza $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Matoska, Vaclav $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Vyhnalek, Martin $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00006350 $t Journal of Alzheimer's disease $x 1875-8908 $g Roč. 102, č. 1 (2024), s. 218-227
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39497316 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104416 $b ABA008
999    __
$a ok $b bmc $g 2263362 $s 1239572
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 102 $c 1 $d 218-227 $e 20241015 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options